



LESOTHO

Number of new cases

2 027

Number of deaths


1 411

Number of prevalent cases (5-year)

3 973


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	1 075 083	1 100 612	2 175 695
Incidence*			
Number of new cancer cases	725	1 302	2 027
Age-standardized incidence rate	108.1	130.4	115.5
Risk of developing cancer before the age of 75 years (cum. risk %)	10.3	12.4	11.2
Top 3 leading cancers (ranked by cases)**	Prostate Kaposi sarcoma Oesophagus	Cervix uteri Breast Oesophagus	Cervix uteri Breast Prostate
Mortality*			
Number of cancer deaths	507	904	1 411
Age-standardized mortality rate	78.0	90.9	82.0
Risk of dying from cancer before the age of 75 years (cum. risk %)	7.3	8.9	8.1
Top 3 leading cancers (ranked by deaths)**	Prostate Oesophagus Kaposi sarcoma	Cervix uteri Breast Oesophagus	Cervix uteri Oesophagus Prostate
Prevalence*			
5-year prevalent cases	1 282	2 691	3 973



Top 5 most frequent cancers**


Males



Rank	Cancer site	Number of cases	Percent
1st	Prostate	181	25.0%
2nd	Kaposi sarcoma	93	12.8%
3rd	Oesophagus	59	8.1%
4th	Colorectum	51	7.0%
5th	Liver	32	4.4%
-	Others	309	42.6%

Number of new cases in 2022, males, all ages


Females



Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	598	45.9%
2nd	Breast	187	14.4%
3rd	Oesophagus	60	4.6%
4th	Kaposi sarcoma	48	3.7%
5th	Colorectum	46	3.5%
-	Others	363	27.9%

Number of new cases in 2022, females, all ages

Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	598	29.5%
2nd	Breast	187	9.2%
3rd	Prostate	181	8.9%
4th	Kaposi sarcoma	141	7.0%
5th	Oesophagus	119	5.9%
-	Others	801	39.5%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Cervix uteri	598	1	29.5	6.1	413	1	29.3	4.5	1 338	33.7
Breast	187	2	9.2	2.0	96	4	6.8	1.0	402	10.1
Prostate	181	3	8.9	3.0	103	3	7.3	1.5	296	7.5
Kaposi sarcoma	141	4	7.0	0.56	84	5	6.0	0.28	283	7.1
Oesophagus	119	5	5.9	0.77	113	2	8.0	0.73	168	4.2
Colorectum	97	6	4.8	0.65	69	6	4.9	0.41	192	4.8
Lung	68	7	3.4	0.47	61	7	4.3	0.43	99	2.5
Liver	52	8	2.6	0.28	52	8	3.7	0.27	70	1.8
NHL	50	9	2.5	0.24	33	9	2.3	0.17	116	2.9
Lip, oral cavity	29	10	1.4	0.23	22	11	1.6	0.17	56	1.4
Stomach	27	11	1.3	0.16	23	10	1.6	0.13	40	1.0
Vulva	27	11	1.3	0.28	18	14	1.3	0.18	66	1.7
Ovary	26	13	1.3	0.29	21	12	1.5	0.26	52	1.3
Bladder	26	13	1.3	0.15	16	15	1.1	0.07	52	1.3
Corpus uteri	22	15	1.1	0.31	8	19	0.57	0.09	52	1.3
Penis	22	15	1.1	0.34	10	17	0.71	0.21	49	1.2
Pancreas	20	17	0.99	0.15	20	13	1.4	0.15	19	0.48
Leukaemia	12	18	0.59	0.05	11	16	0.78	0.04	26	0.65
Larynx	11	19	0.54	0.08	7	22	0.50	0.06	26	0.65
Melanoma	9	20	0.44	0.05	9	18	0.64	0.05	19	0.48
Brain CNS	9	20	0.44	0.04	8	19	0.57	0.04	26	0.65
Hodgkin lymphoma	8	22	0.40	0.03	2	26	0.14	0.01	24	0.60
Multiple myeloma	8	22	0.40	0.06	8	19	0.57	0.06	16	0.40
Oropharynx	6	24	0.30	0.06	6	23	0.43	0.06	11	0.28
Kidney	6	24	0.30	0.04	6	23	0.43	0.04	14	0.35
Thyroid	5	26	0.25	0.05	2	26	0.14	0.03	10	0.25
Vagina	3	27	0.15	0.03	3	25	0.21	0.03	6	0.15
Testis	3	27	0.15	0.02	0	29	0.00	0.00	9	0.23
Mesothelioma	2	29	0.10	0.02	0	29	0.00	0.00	2	0.05
Nasopharynx	1	30	0.05	0.00	1	28	0.07	0.00	2	0.05
Salivary glands	0	31	0.00	0.00	0	29	0.00	0.00	0	0.00
Hypopharynx	0	31	0.00	0.00	0	29	0.00	0.00	0	0.00
All cancers	2 027	-	-	11.2	1 411	-	-	8.1	3 973	-
All cancers excl. NMSC	1 969	-	-	11.0	1 389	-	-	8.0	3 852	-

Data source and methods

Incidence



Country-specific data source: No data
Method: No data: the rates are those of neighbouring countries or registries in the same area

Mortality

Country-specific data source: No data
Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

